Baird Medical's most recent annual filing is a small Chinese thyroid-focused microwave-ablation (MWA) medical-device company that earned a profit in two consecutive years, then lost $27.5M in FY2025 - roughly 122% of FY2025 revenue - on a 39% top-line decline, a $17.5M one-time share-based compensation charge, and a 226% jump in research-and-development spending tied to FDA certification, CE Marking, and an AI ablation system. The same filing walks through a six-factor liquidity defense and concludes the company can continue as a going concern, with cash climbing from $0.2M at year-end to roughly $1.6M by March 31, 2026 after restricted cash was released and related-party support was reaffirmed. The market is not buying it. The stock closed at $1.13 on August 14, 2026 - a 67% drawdown from the 52-week high of $3.44 set in early March, and a 24% gain off the 52-week low of $0.77 touched February 13, 2026. At a market cap of roughly $35M against $19M of bank debt, the company trades at about 1.1x book value and 1.5x FY2025 revenue, which is either a deep value on a franchise that has earned 84% gross margins and held the #1 China position in thyroid MWA needles, or a fair price for a name whose hospitals are paying slower, whose receivables are 76% of revenue, and whose auditor was changed mid-year. The question the next six months will answer is whether the international registrations (Indonesia, Argentina, Pakistan, Malaysia, Vietnam) and the resumed Chinese volume-based-procurement participation show up as actual second-half revenue, or whether the H1 2025 trajectory - revenue already down 39% year over year to $8.0M - extends through FY2026.